Sanofi licenses Sino Biopharm’s transplant drug for $135M upfrontnews2026-03-04T12:05:54+00:00March 4th, 2026|Endpoints News|
UCB boards T cell engager train in $60M upfront deal with Antengenenews2026-03-04T08:51:51+00:00March 4th, 2026|Endpoints News|
Blackstone to support Teva on Sanofi-partnered TL1A with $400Mnews2026-03-04T08:03:51+00:00March 4th, 2026|Endpoints News|
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivantnews2026-03-03T22:30:30+00:00March 3rd, 2026|Endpoints News|
Old school healthcare is warming up to technews2026-03-03T21:46:08+00:00March 3rd, 2026|Endpoints News|
Prime Medicine reverses course to seek FDA approval of shelved therapynews2026-03-03T20:48:13+00:00March 3rd, 2026|Endpoints News|
After years of dispute with FDA, Vanda will get a public hearing for jet lag drugnews2026-03-03T20:21:28+00:00March 3rd, 2026|Endpoints News|
Kyowa Kirin ends OX40 trials after Amgen balked, safety concernnews2026-03-03T20:04:15+00:00March 3rd, 2026|Endpoints News|
FDA explains how some copycat drugs can still win three years of exclusivitynews2026-03-03T18:39:48+00:00March 3rd, 2026|Endpoints News|
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathwaynews2026-03-03T16:33:03+00:00March 3rd, 2026|Endpoints News|
